Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer.

This Chinese expert consensus addresses comprehensive recommendations on biomarker testing, treatment, and follow-up in the perioperative management of patients with resectable ALK-fusion non-small cell lung cancer (NSCLC). The document highlights the pivotal role of cancer genomic testing in informing personalized therapeutic decision-making. The application of perioperative targeted therapies, including alectinib, has demonstrated significant potential in improving clinical outcomes for patients with ALK-fusion NSCLC. The consensus further underscores the necessity for expanded clinical research and trials to optimize and validate individualized treatment strategies, thereby advancing the standard of care in this patient population.